Yeungnam Univ J Med.  2020 Jul;37(3):194-201. 10.12701/yujm.2020.00052.

Polyunsaturated fatty acids, lung function, and health-related quality of life in patients with chronic obstructive pulmonary disease

• Choi H
• Kim T

• KMID: 2506518
• DOI: http://doi.org/10.12701/yujm.2020.00052

Abstract

Background
Dietary polyunsaturated fatty acids (PUFA) are thought to modify systemic inflammation. The present study aimed to evaluate the relationship between PUFA intake, lung function, and health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD).
Methods
In this study, we used the dataset of 6th Korea National Health and Nutrition Examination Survey, in which, a total of 22,948 individuals including 573 participants with a high probability of developing COPD were enrolled. Participants with missing data for the investigated variables were excluded. Linear regression analyses were used to evaluate the association between PUFA intake (omega-3 [N3], omega-6 [N6], and total) with lung function, and HRQoL. HRQoL was determined according to the European Quality of Life-5 Dimensions (EQ-5D). Subgroup analysis of older patients was performed. Age, sex, body mass index, smoking, alcohol, education, residence, total calorie intake, and predicted FEV1% were adjusted in all analyses.
Results
Although lung function was not associated with PUFA intake, EQ-5D index was remarkably associated with N3, N6, and total PUFA intake in a dose-dependent manner. This association was more pronounced in elderly COPD patients. Mean levels of N3, N6, and total PUFA intake were significantly higher in patients having better HRQoL with respect to mobility, self-care, and usual activities.
Conclusion
Our results suggest that N3, N6, and total PUFA intake are associated with HRQoL in COPD patients. This association may be attributed to mobility, self-care, and usual activities. Further longitudinal study is required to clarify this relationship.

Keyword

Chronic obstructive pulmonary disease; KNHANES; Polyunsaturated fatty acid; Quality of life

Figure

• 

  Fig. 1. Flow chart of the study using the dataset of the 6th Korea National Health and Nutrition Examination Survey (KNHANES). FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.

Reference

References

1. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007; 30:993–1013.

2. Zhu B, Wang Y, Ming J, Chen W, Zhang L. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018; 13:1353–64.

3. Kim C, Kim Y, Yang DW, Rhee CK, Kim SK, Hwang YI, et al. Direct and indirect costs of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul). 2019; 82:27–34.

4. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016; 138:16–27.

5. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2:258–66.

6. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7:e37483.

7. Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J. 2018; 52:1801261.

8. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014; 40:315–27.

9. Broekhuizen R, Wouters EF, Creutzberg EC, Weling-Scheepers CA, Schols AM. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax. 2005; 60:376–82.

10. Lemoine S CM, Brigham EP, Woo H, Hanson CK, McCormack MC, Koch A, et al. Omega-3 fatty acid intake and prevalent respiratory symptoms among U.S. adults with COPD. BMC Pulm Med. 2019; 19:97.

11. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014; 43:69–77.

12. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005; 26:319–38.

13. Centers for Disease Control and Prevention (CDC). Vital signs: nonsmokers' exposure to secondhand smoke. United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2010; 59:1141–6.

14. Nolan CM, Longworth L, Lord J, Canavan JL, Jones SE, Kon SS, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016; 71:493–500.

15. Nam H, Kim K, Kwon S, Koh K, Poul K. EQ-5D Korean valuation study using time trade off method. Seoul (KR): Korea Centers for Disease Control and Prevention;2007.

16. Karvetti RL, Knuts LR. Validity of the 24-hour dietary recall. J Am Diet Assoc. 1985; 85:1437–42.

17. Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. 2018 Korean Society for the Study of Obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2019; 28:40–5.

18. Singh D, Vestbo J. Triple therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017; 196:1082–3.

19. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999; 8:209–24.

20. Esquinas C, Ramon MA, Nunez A, Molina J, Quintano JA, Roman-Rodriguez M, et al. Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease. Qual Life Res. 2020; 29:607–17.

21. Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee TA. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med. 2008; 102:519–36.

22. Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest. 2007; 132:1778–85.

23. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019; 53:1900164.

24. Charoenwoodhipong P, Harlow SD, Marder W, Hassett AL, McCune WJ, Gordon C, et al. Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance Program. Arthritis Care Res (Hoboken). 2020; 72:874–8.

25. Behboudi-Gandevani S, Hariri FZ, Moghaddam-Banaem L. The effect of omega 3 fatty acid supplementation on premenstrual syndrome and health-related quality of life: a randomized clinical trial. J Psychosom Obstet Gynaecol. 2018; 39:266–72.

26. Moeinzadeh F, Shahidi S, Mortazavi M, Dolatkhah S, Kajbaf M, Haghjooy Javanmard S, et al. Effects of omega-3 fatty acid supplementation on serum biomarkers, inflammatory agents, and quality of life of patients on hemodialysis. Iran J Kidney Dis. 2016; 10:381–7.

27. Croasdell A, Thatcher TH, Kottmann RM, Colas RA, Dalli J, Serhan CN, et al. Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. Am J Physiol Lung Cell Mol Physiol. 2015; 309:L888–901.

28. Baylin A, Campos H. Arachidonic acid in adipose tissue is associated with nonfatal acute myocardial infarction in the central valley of Costa Rica. J Nutr. 2004; 134:3095–9.

29. Kaikkonen JE, Kresanov P, Ahotupa M, Jula A, Mikkila V, Viikari JS, et al. High serum n6 fatty acid proportion is associated with lowered LDL oxidation and inflammation: the Cardiovascular Risk in Young Finns Study. Free Radic Res. 2014; 48:420–6.

30. Noguchi H, Nishi D, Matsumura K, Hamazaki K, Hamazaki T, Matsuoka YJ. Limited effect of omega-3 fatty acids on the quality of life in survivors of traumatic injury: a randomized, placebo-controlled trial. Prostaglandins Leukot Essent Fatty Acids. 2017; 127:1–5.